While patients with these co-mutations have poor clinical outcomes and a more aggressive malignancy that frequently develops brain metastases [6,7], there are currently no therapies available to cure KRAS/LKB1 (KL) co-mutant NSCLC. The gene discussed is KL; the disease is non-small cell lung carcinoma.